english.prescrire.org > Spotlight > 100 most recent > Ibrutinib: increased risk of sudden death

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Ibrutinib: increased risk of sudden death

 Adverse Effects  Data from clinical trials show a 5-fold greater risk of sudden or cardiac death with ibrutinib than with comparators.

In late 2022, the company which markets ibrutinib reported that "assessment of data from the randomised clinical trials pool of ibrutinib" showed that the crude incidence of sudden or cardiac death was approximately 5 times higher in patients taking ibrutinib (5 cardiac deaths per 1000 patients) than in other groups (1 death per 1000)...

©Prescrire 1 April 2023

Source: "Ibrutinib: increased risk of sudden death" Prescrire International 2023; 32 (247): 104-105. Subscribers only.

Enjoy full access to Prescrire International, and support independent information

Share
Share on  Facebook Share on  Twitter


Read more:

All the subjects in
Prescrire's Spotlight
Free >